Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
Research and development expenses for the third quarter of 2025 were $14.0 million, compared with $11.6 million for the third quarter in 2024. The increase was primarily due to additional costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback